Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7.3BCash on Hand
CF+ Cash Runway
Follow ABT by emailGet an email when ABT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ABT, unsubscribe in one click. Privacy
📣 What ABT Says Is Next
in 2026 · “In addition to these strategic price actions, Abbott expects to increase volume growth with the launch of several new products in 2026.”
Company press release, Jan 22, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
🧪 Trial & FDA Catalysts
Nov 2026 · N/A · Recruiting · Grid eXplore Mapping Study Registry primary completion date, not a results date
Dec 2026 · N/A · Recruiting · Glycemic Metrics and Patterns in People With and Without Prediabetes Registry primary completion date, not a results date
Dec 2026 · N/A · Recruiting · Acute Response to Left Bundle Branch Area Pacing With SyncAV Registry primary completion date, not a results date
Dec 2026 · N/A · Active Trial · FSL2 Post Approval Study for Pediatric and Young Adults Patients Registry primary completion date, not a results date
Dec 2026 · N/A · Recruiting · Cephea Early Feasibility Study Registry primary completion date, not a results date
Dec 2026 · N/A · Recruiting · A Clinical Evaluation of AMJ-401 Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not ABT's own candidates): Carboplatin, Paclitaxel.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ABT holds $7.3B in cash and short-term investments (as of Mar 31, 2026) and its operations are currently cash-flow neutral or positive.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.